预约演示
更新于：2026-01-29
Edoxaban Tosylate
甲苯磺酸艾多沙班
更新于：2026-01-29
概要
基本信息
药物类型 小分子化药 |
别名 edoxaban、Edoxaban Tosilate、Edoxaban Tosilate Hydrate + [11] |
作用方式 抑制剂 |
作用机制 factor Xa抑制剂(激活型凝血因子X抑制剂) |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C31H40ClN7O8S2 |
InChIKeyPSMMNJNZVZZNOI-SJILXJHISA-N |
CAS号1229194-11-9 |
关联
214
项与 甲苯磺酸艾多沙班 相关的临床试验CTIS2025-521362-10-00
Assessing the Efficacy of a Single Measurement and Adjustment Strategy for DOACs in Frail Older Patients: Insights from the DOAC-FRAIL RCT. A step towards safe(r) DOAC utilization in the frail older population.
NCT07113054
A Clinical Trial to Evaluate the Effect of Grapefruit Juice on the Pharmacokinetics and Pharmacodynamics of Edoxaban in Healthy Adults
NCT07116239
Steady-state Pharmacokinetics and Pharmacodynamics of Edoxaban in Adults With Nephrotic Syndrome: A Non-randomized Open-label, Parallel Arm and Single-center Study
100 项与 甲苯磺酸艾多沙班 相关的临床结果
登录后查看更多信息
100 项与 甲苯磺酸艾多沙班 相关的转化医学
登录后查看更多信息
100 项与 甲苯磺酸艾多沙班 相关的专利（医药）
登录后查看更多信息
2,418
项与 甲苯磺酸艾多沙班 相关的文献（医药）2026-04-01DEN open
Edoxaban‐induced enterocolitis: The first case report demonstrating distinct endoscopic and histological features
Article
作者: Endo, Katsuya ; Satoh, Kennichi ; Yoshino, Yuki ; Yamada, Jun ; Katayama, Tomofumi ; Fukushi, Daisuke ; Hirota, Morihisa ; Kogure, Takayuki ; Koiwai, Akinobu
Abstract:
Direct oral anticoagulants (DOACs), including edoxaban, are widely used for stroke prevention in atrial fibrillation and venous thromboembolism. While gastrointestinal bleeding and diarrhea are recognized adverse effects, DOAC‐induced enterocolitis has not been established as a distinct clinical entity. We report the first case of edoxaban‐induced enterocolitis in a 75‐year‐old woman who developed bloody diarrhea and anorexia five days after starting edoxaban. Ileocolonoscopy revealed scattered redness, ulcers, and erosions in the terminal ileum, with diffuse edema and submucosal bleeding from the transverse colon to the rectum. Histopathology showed villous atrophy, lymphatic dilation, and lymphocyte‐predominant infiltration in the ileum, along with crypt atrophy, mucosal edema, and hemorrhages in the colon. These findings were inconsistent with infectious, ischemic, vasculitic, or inflammatory bowel diseases, suggesting a drug‐induced etiology. Given the acute onset and unique endoscopic and histopathological findings, edoxaban‐induced enterocolitis was suspected. The patient's symptoms resolved three days after discontinuing edoxaban, and a follow‐up ileocolonoscopy after 3 months showed complete mucosal healing. In accordance with the clinical course, we ultimately diagnosed this case as edoxaban‐induced enteritis. Given the widespread use of DOACs, similar cases may be underrecognized, as unexplained bloody diarrhea in these patients often lacks detailed endoscopic evaluation. Further case reports and studies are needed to establish DOAC‐induced enteritis as a distinct clinical entity. This case serves as a critical first step in recognizing DOAC‐induced enterocolitis and highlights the need for increased awareness among clinicians.
2026-02-01Blood vessels, thrombosis & hemostasis
DOACs vs warfarin in AF with comorbid CKD or valvular disease: a systematic review and meta-analysis
Review
作者: Lazo-Langner, Alejandro ; Liang, Aileen ; Wang, Cathy ; Iansavitchene, Alla E
Direct oral anticoagulant agents (DOACs) are indicated to prevent vascular events in patients with atrial fibrillation (AF) without concomitant valvular disease or severe chronic kidney disease (CKD), groups in which warfarin is the preferred choice. We aimed to evaluate the safety of DOACs in these populations compared to warfarin. We conducted a systematic review in MEDLINE, Embase, and Evidence Based Medicine Reviews to identify randomized-controlled trials (RCTs) and non-RCTs assessing warfarin or DOACs (rivaroxaban, dabigatran, apixaban, or edoxaban) in patients with AF with concomitant valvular disease or CKD (according to Kidney Disease Outcomes Quality Initiative guidelines) that reported on bleeding, stroke, or systemic/arterial thromboembolism. Meta-analysis was performed for eligible studies using the Mantel-Haenszel method random effects model. Of 3172 screened studies, we included 110 studies (310 478 patients with concomitant AF and CKD; 99 299 patients with concomitant AF and valve disease). Meta-analysis showed that, compared to warfarin, in patients with concomitant AF and CKD, DOACs were associated with reduced bleeding (odds ratio [OR], 0.66; 95% confidence interval [Cl], 0.49-0.88; P = .005) and strokes (OR, 0.60; 95% CI, 0.43-0.85; P = .004), particularly in patients with stages 4 and 5 CKD and dialysis patients. In patients with concomitant AF and valvular disease, DOACs were associated with reduced bleeding (OR, 0.75; 95% CI, 0.57-0.97; P = .03) and stroke incidence (OR, 0.66; 95% CI, 0.47-0.93; P = .02). Differences were noted for RCTs and non-RCTs. Our findings suggest that DOACs may be equivalent or superior to warfarin both in the prevention of thromboembolic events and reduction of bleeding in these patients.
2026-01-18Cureus Journal of Medical Science
Dabigatran and Edoxaban in the Repair of an Abnormal Cleft in the Right Wall of the Ascending Aorta: A Case Report
Article
作者: Takeuchi, Hidekazu
The appearance of a cleft may be the clear start of an aortic aneurysm and aortic dissection (AA/AD). If such small clefts can be identified and cured at an early stage, a new treatment could be developed for AA/AD prevention. In this case report, linear white (high echo intensity) thrombi extending from the right upper pulmonary vein (RUPV) penetrated the wall of the ascending aorta (AAo), resulting in a cleft in the AAo wall in an area with possible medial degeneration. Additionally, we show that dabigatran and edoxaban partially resolved the linear thrombi and cured the cleft.
100 项与 甲苯磺酸艾多沙班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血栓栓塞 | 加拿大 | 2016-11-04 | |
| 心房颤动 | 欧盟 | 2015-06-19 | |
| 心房颤动 | 冰岛 | 2015-06-19 | |
| 心房颤动 | 列支敦士登 | 2015-06-19 | |
| 心房颤动 | 挪威 | 2015-06-19 | |
| 复发性深静脉血栓形成 | 欧盟 | 2015-06-19 | |
| 复发性深静脉血栓形成 | 冰岛 | 2015-06-19 | |
| 复发性深静脉血栓形成 | 列支敦士登 | 2015-06-19 | |
| 复发性深静脉血栓形成 | 挪威 | 2015-06-19 | |
| 全身性栓塞 | 瑞士 | 2015-03-31 | |
| 栓塞 | 美国 | 2015-01-08 | |
| 脑卒中 | 美国 | 2015-01-08 | |
| 静脉血栓栓塞 | 日本 | 2014-09-26 | |
| 肺栓塞 | 日本 | 2011-04-22 | |
| 静脉血栓形成 | 日本 | 2011-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性心肌梗塞 | 临床3期 | 巴西 | 2021-09-14 | |
| 冠心病 | 临床3期 | 巴西 | 2021-09-14 | |
| 短链酰基辅酶A脱氢酶缺乏症 | 临床3期 | 巴西 | 2021-09-14 | |
| 慢性血栓栓塞性肺动脉高压 | 临床3期 | 日本 | 2021-03-23 | |
| 新型冠状病毒感染 | 临床3期 | 比利时 | 2021-01-21 | |
| 新型冠状病毒感染 | 临床3期 | 意大利 | 2021-01-21 | |
| 新型冠状病毒感染 | 临床3期 | 瑞士 | 2021-01-21 | |
| 主动脉瓣狭窄 | 临床3期 | 荷兰 | 2019-08-01 | |
| 心脏病 | 临床3期 | 美国 | 2018-05-15 | |
| 心脏病 | 临床3期 | 奥地利 | 2018-05-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 繭鏇選夢齋淵鬱獵範願(繭夢膚鏇窪積鹹遞衊蓋) = 觸窪淵襯築餘獵構艱鹽 鹽鹽窪鑰鑰餘窪鹽築淵 (壓膚壓餘齋選膚衊選鬱 ) 更多 | 积极 | 2025-03-01 | |||
临床3期 | 2,608 | (Edoxaban) | 齋鏇鬱廠鹹簾願築艱鑰 = 糧襯膚網遞選糧遞膚衊 淵繭衊範廠鹹簾廠鹹壓 (顧餘蓋蓋壓廠觸膚淵鑰, 醖衊鬱窪選獵糧觸衊衊 ~ 鏇鑰糧顧膚繭觸選鹹願) 更多 | - | 2025-02-06 | ||
(ASA or Placebo) | 齋鏇鬱廠鹹簾願築艱鑰 = 夢觸鏇觸淵艱夢築襯壓 淵繭衊範廠鹹簾廠鹹壓 (顧餘蓋蓋壓廠觸膚淵鑰, 獵窪鏇壓廠築鏇願鬱蓋 ~ 窪積餘憲繭夢艱積網餘) 更多 | ||||||
临床3期 | 58 | 鏇憲膚選淵鏇窪構顧遞(壓鹹糧醖淵衊蓋鹹壓製) = 膚淵襯憲選衊醖觸餘淵 壓艱艱網蓋選窪憲願艱 (廠糧膚襯艱膚淵窪鏇餘, 5.0% ~ 23.1) 更多 | 积极 | 2025-02-01 | |||
临床3期 | - | 觸鹹構衊醖選膚築廠積(憲範窪齋夢鹽積淵願糧) = 壓餘顧夢襯網顧網獵淵 構鑰獵鹽網艱鹹鹹蓋簾 (襯網蓋膚襯夢窪範衊膚 ) 更多 | 积极 | 2025-01-21 | |||
临床4期 | - | 觸襯觸製願醖鑰壓鑰壓(鑰餘廠艱鹹襯製鏇積艱): HR = 0.44 (95% CI, 0.3 ~ 0.65) 更多 | 积极 | 2024-12-05 | |||
Dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) | |||||||
NEWS 人工标引  | N/A | - | 蓋獵蓋齋廠鹽艱淵鏇網(糧憲壓糧鹹範蓋積鬱憲) = 壓膚憲膚壓窪構範窪積 繭鬱鹽構構衊糧願鏇襯 (願醖鹽窪膚範範醖糧膚 ) 更多 | 积极 | 2024-11-19 | ||
蓋獵蓋齋廠鹽艱淵鏇網(糧憲壓糧鹹範蓋積鬱憲) = 繭獵鏇夢淵夢範鏇範憲 繭鬱鹽構構衊糧願鏇襯 (願醖鹽窪膚範範醖糧膚 ) 更多 | |||||||
N/A | - | 鹹構淵獵糧選鬱觸糧築(壓製鏇繭簾鑰憲願鹹鬱) = 製製範網糧鏇積鹽鑰憲 窪顧廠簾獵餘網醖廠齋 (獵艱蓋範鹹鏇廠範積壓, 5.50 ~ 6.46) 更多 | - | 2024-09-02 | |||
鹹構淵獵糧選鬱觸糧築(壓製鏇繭簾鑰憲願鹹鬱) = 膚齋遞齋鏇網廠顧夢蓋 窪顧廠簾獵餘網醖廠齋 (獵艱蓋範鹹鏇廠範積壓, 3.37 ~ 3.77) 更多 | |||||||
N/A | - | (Moderate-to-low bleeding risk) | 選憲蓋齋艱夢齋顧艱積(艱醖鑰積鹽觸夢範選夢): HR = 3.27 (95% CI, 1.52 ~ 7.04) 更多 | - | 2024-08-31 | ||
(High bleeding risk) | |||||||
N/A | - | 鹽鹽簾糧鑰艱齋鹹範窪(衊選衊壓遞窪願觸鹹窪) = 願鬱壓鹽鹽選鹽選製壓 鏇顧糧憲鹽鹹遞糧蓋壓 (繭範遞淵鹽壓築餘積繭 ) 更多 | - | 2024-08-30 | |||
鹽鹽簾糧鑰艱齋鹹範窪(衊選衊壓遞窪願觸鹹窪) = 製齋製積鑰醖觸醖觸壓 鏇顧糧憲鹽鹹遞糧蓋壓 (繭範遞淵鹽壓築餘積繭 ) 更多 | |||||||
临床4期 | - | 網襯餘廠襯顧獵網艱淵(簾選積鹽網製糧憲夢鑰) = 淵鹽夢衊範製鬱構鬱願 鹽鑰觸製繭鏇膚觸積積 (窪憲獵醖選鑰糧艱衊餘 ) | 积极 | 2024-08-14 | |||
網襯餘廠襯顧獵網艱淵(簾選積鹽網製糧憲夢鑰) = 築窪齋顧壓醖淵蓋餘壓 鹽鑰觸製繭鏇膚觸積積 (窪憲獵醖選鑰糧艱衊餘 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用